Home Cart Sign in  
Chemical Structure| 26040-51-7 Chemical Structure| 26040-51-7

Structure of 26040-51-7

Chemical Structure| 26040-51-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Morris, Johnathan James ;

Abstract: The increase in commercially used chemicals that are inadequately evaluated for safety and risk to development has created a reticent threat to human health. Addressing these deficiencies is compounded by limited methodologies to determine the etiology of exposure-related developmental neurotoxicity (DNT). Current means of assessing DNT are largely retrospective and limited by the expensive, time-consuming, and labor-intensive use of laboratory animal models, thereby motivating a global research effort to produce alternative chemical screening assays. In this work, we have developed a novel high-throughput platform that serves as a new tool to evaluate the effects of exogenous chemical exposure on developmental processes in the non-vertebrate animal model, Schmidtea mediterranea (Smed). We demonstrate that light avoidance in Smed is a robust behavior that can be assayed throughout head regeneration and is temporally correlated to the anatomical development of central nervous system structure. Thus, reacquisition of this behavior serves as a surrogate measure of neurodevelopment that can be utilized to characterize exposure-related effects in DNT. Our high-throughput screening platform enables a more sensitive classification of these responses and assesses both endpoint and temporal effects of chemical exposure in DNT, which paves the way for more exhaustive and predictive chemical assessment to minimize the impact on human health.

Purchased from AmBeed:

Alternative Products

Product Details of [ 26040-51-7 ]

CAS No. :26040-51-7
Formula : C24H34Br4O4
M.W : 706.14
SMILES Code : O=C(OCC(CC)CCCC)C1=C(Br)C(Br)=C(Br)C(Br)=C1C(OCC(CC)CCCC)=O
MDL No. :MFCD01941091
InChI Key :UUEDINPOVKWVAZ-UHFFFAOYSA-N
Pubchem ID :117291

Safety of [ 26040-51-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H227-H315-H319-H335
Precautionary Statements:P305+P351+P338

Computational Chemistry of [ 26040-51-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 32
Num. arom. heavy atoms 6
Fraction Csp3 0.67
Num. rotatable bonds 16
Num. H-bond acceptors 4.0
Num. H-bond donors 0.0
Molar Refractivity 147.1
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

52.6 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

5.1
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

10.65
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

9.48
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

7.24
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

9.81
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

8.46

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-10.01
Solubility 0.000000069 mg/ml ; 0.0000000001 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Insoluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-11.71
Solubility 0.0000000014 mg/ml ; 0.0 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Insoluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-10.43
Solubility 0.0000000265 mg/ml ; 0.0 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Insoluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

Low
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

Yes
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-3.05 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

2.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

1.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

1.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

3.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.17

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

3.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<3.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

4.63
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 26040-51-7 ]

Aryls

Chemical Structure| 1131587-91-1

A131246 [1131587-91-1]

Ethyl 5-bromo-2,4-dimethylbenzoate

Similarity: 0.85

Chemical Structure| 99548-56-8

A182378 [99548-56-8]

Methyl 2-bromo-6-methylbenzoate

Similarity: 0.85

Chemical Structure| 859299-66-4

A108270 [859299-66-4]

Dimethyl 4,5-dibromophthalate

Similarity: 0.84

Chemical Structure| 86246-71-1

A904450 [86246-71-1]

Methyl 3-bromo-2,6-dimethylbenzoate

Similarity: 0.84

Chemical Structure| 152849-72-4

A232176 [152849-72-4]

Methyl 5-bromo-2,4-dimethylbenzoate

Similarity: 0.82

Bromides

Chemical Structure| 1131587-91-1

A131246 [1131587-91-1]

Ethyl 5-bromo-2,4-dimethylbenzoate

Similarity: 0.85

Chemical Structure| 99548-56-8

A182378 [99548-56-8]

Methyl 2-bromo-6-methylbenzoate

Similarity: 0.85

Chemical Structure| 859299-66-4

A108270 [859299-66-4]

Dimethyl 4,5-dibromophthalate

Similarity: 0.84

Chemical Structure| 86246-71-1

A904450 [86246-71-1]

Methyl 3-bromo-2,6-dimethylbenzoate

Similarity: 0.84

Chemical Structure| 152849-72-4

A232176 [152849-72-4]

Methyl 5-bromo-2,4-dimethylbenzoate

Similarity: 0.82

Esters

Chemical Structure| 1131587-91-1

A131246 [1131587-91-1]

Ethyl 5-bromo-2,4-dimethylbenzoate

Similarity: 0.85

Chemical Structure| 99548-56-8

A182378 [99548-56-8]

Methyl 2-bromo-6-methylbenzoate

Similarity: 0.85

Chemical Structure| 859299-66-4

A108270 [859299-66-4]

Dimethyl 4,5-dibromophthalate

Similarity: 0.84

Chemical Structure| 86246-71-1

A904450 [86246-71-1]

Methyl 3-bromo-2,6-dimethylbenzoate

Similarity: 0.84

Chemical Structure| 152849-72-4

A232176 [152849-72-4]

Methyl 5-bromo-2,4-dimethylbenzoate

Similarity: 0.82